


AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A compound of the formula I:




wherein

~~M represents a macrolide subunit possessing the property of accumulation in inflammatory cells;~~

M represents a group of

Formula II:



II

wherein:

- (i) Z and W independently are: $>C=O$, $>CH_2$, $>CH-NR_tR_s$, $>N-R_N$ or $>C=N-R_M$ or a bond wherein:

R_t and R_s independently are hydrogen or alkyl;

R_M is hydroxy, alkoxy, substituted alkoxy or OR^P ;


R_N is hydrogen, R^P , alkyl, alkenyl, alkynyl, alkoxy, alkoxyalkyl, or

$-C(X)-NR_tR_s$; wherein X is $=O$ or $=S$;

provided that Z and W cannot both simultaneously be, $>C=O$, $>CH_2$,

$>CH-NR_tR_s$, $>N-R_N$ or $>C=N-R_M$ or a bond,

- (ii) U and Y independently are hydrogen, halogen, alkyl, or hydroxyalkyl;
 (iii) R^1 is hydroxy, OR^P , $-O-S^2$ group or an $=O$;
 (iv) S^1 is a sugar moiety of formula:




wherein

R^8 and R^9 are both hydrogen or together form a bond, or R^9 is hydrogen and R^8 is - $N(CH_3)R^y$, wherein

R^y is R^P , R^Z or $-C(O)R^Z$ wherein R^Z is hydrogen or alkyl or alkenyl or alkynyl or cycloalkyl or aryl or heteroaryl or alkyl substituted with C_2 - C_7 -alkyl, C_2 - C_7 -alkenyl, C_2 - C_7 -alkynyl, aryl or heteroaryl

R^{10} is hydrogen or R^P ;

- (v) S^2 is a sugar moiety of formula :



wherein:

R^{3'} is hydrogen or methyl;

R¹¹ is hydrogen, R^p or O-R¹¹ is a group that with R¹² and with C/4'' carbon atom forms a >C=O or epoxy group;

R¹² is hydrogen or a group that with O-R¹¹ group and with C/4'' carbon atom forms a >C=O or epoxy group;

(vi) R² is hydrogen, hydroxy, OR^p or alkoxy

(vii) A is hydrogen or methyl;

(viii) B is methyl or epoxy;

(ix) E is hydrogen or halogen;

(x) R³ is hydroxy, OR^p, alkoxy or R³ is a group that with R⁵ and with C/11 and C/12 carbon atoms forms a cyclic carbonate or carbamate; or if W or Z is >N-R_N R³ is a group that with W or Z forms a cyclic carbamate;

(xi) R⁴ is C₁-C₄ alkyl;

(xii) R⁵ is hydrogen, hydroxy, OR^p, C₁-C₄-alkoxy, or a group that with R³ and with C/11 and C/12 carbon atoms forms a cyclic carbonate or carbamate;

(xiii) R⁶ is hydrogen or C₁-C₄-alkyl;


wherein M has a linkage site through which it is linked to V via linking group L; provided that the linkage site being at one or more of the following:

- a) any reactive hydroxy, nitrogen, or epoxy group located on S¹, S², or an aglycone oxygen if S¹ or/and S² is cleaved off;
- b) a reactive >N-R_N or -NR₁R_s or =O group located on Z or W;
- c) a reactive hydroxy group located at any one of R¹, R², R³, and R⁵;

d) any other group that can be first derivatized to a hydroxy or -NR_iR_s group and

R^p is hydroxyl or amino protective group;

V is chosen from the group consisting of (i) an anti-inflammatory steroid subunit of the Formula X:



X

wherein

R^a and R^b independently represents, hydrogen or halogen;

R^c is hydroxy, alkoxy, alkyl, thiocarbamoyl, carbamoyl or a valence-bond;

R^d and R^e independently represents: hydrogen, hydroxy, methyl or C₁-C₄-alkoxy or each are a group that forms a 1,3-dioxolane ring with the other or a valence bond;

R^f is hydrogen, hydroxy, chloro, or forming a keto group with the carbon atom it is attached to;

R^j is hydrogen or halogen ;

or (ii) a non-steroidal anti-inflammatory subunit derived from the NSAIDs selected from:

aceclofenac, acemetacin, acetaminophen, acetaminosalol, acetyl-salicylic acid, acetyl-salicylic-2-

amino-4-picoline-acid, 5-aminoacetylsalicylic acid, alclofenac, aminoprofen, amfenac, ampyrone, ampiroxicam, anileridine, bendazac, benoxaprofen, bermoprofen, α -bisabolol, bromfenac, 5-bromosalicylic acid acetate, bromosaligenin, bucloxic acid, butibufen, carprofen, celexocib, chromoglycate, cinmetacin, clindanac, clopirac, sodium diclofenac, diflunisal, ditazol, droxicam, enfenamic acid, etodolac, etofenamate, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentiazac, fepradinol, flufenac, flufenamic acid, flunixin, flunoxaprofen, flurbiprofen, glutametacin, glycol salicylate, ibufenac, ibuprofen, ibuproxam, indomethacin, indoprofen, isofezolac, isoxepac, isoxicam, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, metiazinic acid, mofezolac, montelukast, nabumetone, naproxen, niflumic acid, nimesulide, olsalazine, oxaceprol, oxaprozin, oxyphenbutazone, paracetamol, parsalimide, perisoxal, phenyl-acethyl-salicylate, phenylbutazone, phenylsalicylate, pyrazolac, piroxicam, pirprofen, pranoprofen, protizinic acid, reserveratol, salacetamide, salicylamide, salicylamide-O-acetyl acid, salicylsulphuric acid, salicin, salicylamide, salsalate, sulindac, suprofen, suxibutazone, tamoxifen, tenoxicam, tiaprofenic acid, tiaramide, ticlopridine, tinoridine, tolfenamic acid, tolmetin, tropesin, xenbucin, ximoprofen, zaltoprofen, zomepirac, tomoxiprol, zafirlukast and cyclosporine;


or (iii) an antineoplastic subunit derived from the antineoplastic compounds selected from bicalutamide, camptothecin, estramustine phosphate, flutamide, mechlorethamine, thiotepa, ifosfamide, hydroxyurea, bleomycin, paclitaxel, lomustine, irinotecan, methotrexate, vinorelbine, anastrozole, floxuridine, melphalan, vincristine, vinblastine, mitomycin, nandrolone, goserelin, leuprolide, triptorelin, aminogluthetamide, mitotane, cisplatin, chlorambucil, pentostatin, cladribine, busulfan, etoposide, mitoxantrone, idarubicin, cyclophosphamide, mercaptopurine,

thioguanine, cytarbine, cyclophosphamide, doxorubicin, daunoribicin, teniposide tamoxifen,
taxotere and topotecan;


or and (iv) an antiviral subunit derived from the anti-viral compounds selecting from aciclovir, famciclovir, ganciclovir, cidofovir, lamivudine, ritonavir, indinavir, nevirapine, zidovudine, didanosine, stavudine, abacavir, zalcitabine, amprenavir, ribavirin and adamantane; and

L is a linker molecule to which each of **M** and **V** are covalently linked; and pharmaceutically acceptable salts and solvates thereof and individual diastereoisomers thereof.

2. (Currently Amended) A compound according to ~~claim 1~~ of the formula I:



wherein **M** represents a group of
Formula II:




Docket No.: 03818/100L652-US1

R^y is R^p, R^z or -C(O)R^z wherein R^z is hydrogen or alkyl or alkenyl or alkynyl or cycloalkyl or aryl or heteroaryl or alkyl substituted with C₂-C₇-alkyl, C₂-C₇-alkenyl, C₂-C₇-alkynyl, aryl or heteroaryl

R^{10} is hydrogen or R^p ;

(v) S^2 is a sugar moiety of formula :



wherein:

R^{3'} is hydrogen or methyl;

R¹¹ is hydrogen, R^p or O-R¹¹ is a group that with R¹² and with C/4" carbon atom forms a >C=O or epoxy group;

R¹² is hydrogen or a group that with O-R¹¹ group and with C/4" carbon atom forms a >C=O or epoxy group;

(vi) R^2 is hydrogen, hydroxy, OR^p or alkoxy

(vii) A is hydrogen or methyl;

(viii) B is methyl or epoxy;

(ix) E is hydrogen or halogen;

(x) R³ is hydroxy, OR^b, alkoxy or R³ is a group that with R⁵ and with C/11 and C/12 carbon atoms forms a cyclic carbonate or carbamate; or if W or Z is >N-R_N R³ is a group that with W or Z forms a cyclic carbamate;

(xi) R^4 is C_1 - C_4 alkyl;

(xii) R⁵ is hydrogen, hydroxy, OR^p, C₁-C₄-alkoxy, or a group that with R³ and with C/11 and C/12 carbon atoms forms a cyclic carbonate or carbamate;


(xiii) R^6 is hydrogen or C_1 - C_4 -alkyl;

wherein **M** has a linkage site through which it is linked to **V** *via* linking group **L**; provided that the linkage site being at one or more of the following:

- any reactive hydroxy, nitrogen, or epoxy group located on S^1 , S^2 , or an aglycone oxygen if S^1 or/and S^2 is cleaved off;
- a reactive $>N-R_N$ or $-NR_tR_s$ or $=O$ group located on Z or W;
- a reactive hydroxy group located at any one of R^1 , R^2 , R^3 , and R^5 ;
- any other group that can be first derivatized to a hydroxy or $-NR_tR_s$ group and

R^p is hydroxyl or amino protective group,

wherein L is group of Formula IV:



IV

wherein

X¹ is selected from: -CH₂-, -C(O)-, OC(O)-, N-O-, -OC(O)NH- or -C(O)NH-;

X² is -NH- or -NHC(O)-, -OC(O)-, -C(O)-, -O or -CH₂-;

Q is -NH- or -CH₂-, or absent;

wherein each -CH₂- or -NH- group may be optionally substituted by C₁-C₇-alkyl,

C₂-C₇-alkenyl, C₂-C₇-alkynyl, C(O)R^x, C(O)OR^x, C(O)NHR^x wherein R^x may be

C₁-C₇-alkyl, aryl or heteroaryl;


the symbols m and n independently are a whole number from 0 to 4, with the proviso that if Q is

NH, n cannot be 0.

with proviso that if L is group of Formula IV, V is an antineoplastic subunit or an antiviral subunit;

L represents a polypeptide of between about two and about 50 amino acids joined together;

wherein V is selected from the group consisting of (i) an antiinflammatory steroid subunit of the Formula X:



wherein

R^a and R^b independently represents, hydrogen or halogen;

R^c is hydroxy, alkoxy, alkyl, thiocarbamoyl, carbamoyl or a valence-bond;

R^d and R^e independently represents: hydrogen, hydroxy, methyl or C₁-C₄-alkoxy or each are a group that forms a 1,3-dioxolane ring with the other or a valence bond;

R^f is hydrogen, hydroxy, chloro, or forming a keto group with the carbon atom it is attached to;

R^j is hydrogen or halogen;

and pharmaceutically acceptable salts and solvates of any of the foregoing.

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Original) A compound according to claim 2 wherein Z and W together are: -
N(CH₃)-CH₂-, -NH-CH₂-, -CH₂-NH-, -C(O)-NH- or -NH-C(O)-;

A and B are methyl;

E is hydrogen;

R² is hydroxy or methoxy;

S¹ represents desosamine sugar wherein R⁸ is selected from: hydrogen, methyl,

amino, C₁-C₆ alkylamino or C₁-C₆ dialkylamino;

R⁹ and R¹⁰ are hydrogen;

R¹ is hydroxy or the O-S² group wherein the S² represents a cladinose sugar wherein:

R¹¹ is hydrogen, or O-R¹¹ is a group that with R¹² and with C/4" carbon atom forms a >C=O or

epoxy group; R¹² is hydrogen or a group that with O-R¹¹ and with C/4" carbon atom forms a >C=O

or epoxy group;


12. (Currently Amended) A compound according to claim [[7]] 2 wherein:

V is derived from an antineoplastic compounds selecting from: methotrexate, paclitaxel, camptothecin and doxorubicin.

13. (Currently Amended) A compound according to claim [[8]] 2 wherein


V is derived from the anti-viral compounds selected from: the group consisting of: zidovudine, didanosine and stavudine.

14. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

15. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

16. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

17. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

18. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

19. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

20. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

21. (Currently Amended) A compound of the Formula:




22. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

23. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

24. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

25. (Currently Amended) A compound of the Formula:



and pharmaceutically acceptable salts and solvates thereof.


26. (Currently Amended) A compound of the Formula:



and pharmaceutically acceptable salts and solvates thereof.


27. (Currently Amended) A compound of the Formula:

29. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

30. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

31. (Currently Amended) A compound of the Formula:




34. (Currently Amended) A compound of the Formula:




and pharmaceutically acceptable salts and solvates thereof.

35. (Currently Amended) A compound of the Formula:




36. (Currently Amended) Process for the preparation of a compound of Formula I



I

M represents a group of
Formula II:




wherein

R^8 and R^9 are both hydrogen or together form a bond, or R^9 is hydrogen and R^8 is - $N(CH_3)R^y$, wherein

R^y is R^p , R^z or $-C(O)R^z$ wherein R^z is hydrogen or alkyl or alkenyl or alkynyl or cycloalkyl or aryl or heteroaryl or alkyl substituted with C_2 - C_7 -alkyl, C_2 - C_7 -alkenyl, C_2 - C_7 -alkynyl, aryl or heteroaryl

R^{10} is hydrogen or R^p ;

(v) S^2 is a sugar moiety of formula :



wherein:

$R^{3'}$ is hydrogen or methyl;

R^{11} is hydrogen, R^p or $O-R^{11}$ is a group that with R^{12} and with C/4'' carbon atom forms a $>C=O$ or epoxy group;

R^{12} is hydrogen or a group that with $O-R^{11}$ group and with C/4'' carbon atom forms a $>C=O$ or epoxy group;

(vi) R^2 is hydrogen, hydroxy, OR^p or alkoxy

(vii) A is hydrogen or methyl;

(viii) B is methyl or epoxy;

X

wherein

R^a and R^b independently represents, hydrogen or halogen;

R^c is hydroxy, alkoxy, alkyl, thiocarbamoyl, carbamoyl or a valence-bond;


R^d and R^e independently represents: hydrogen, hydroxy, methyl or C₁-C₄-alkoxy or each are a group that forms a 1,3-dioxolane ring with the other or a valence bond;

R^f is hydrogen, hydroxy, chloro, or forming a keto group with the carbon atom it is attached to;

R^j is hydrogen or halogen;


(ii) a non-steroidal anti-inflammatory subunit derived from the NSAID selected from the group consisting of: aceclofenac, acemetacin, acetaminophen, acetaminosalol, acetyl-salicylic acid, acetyl-salicylic-2-amino-4-picoline-acid, 5-aminoacetylsalicylic acid, alclofenac, aminoprofen, amfenac, ampyrone, ampiroxicam, anileridine, bendazac, benoxaprofen, bermoprofen, α -bisabolol, bromfenac, 5-bromosalicylic acid acetate, bromosaligenin, bucloxic acid, butibufen, carprofen, celecoxib, chromoglycate, cinmetacin, clindanac, clopirac, sodium diclofenac, diflunisal, ditazol, droxicam, enfenamic acid, etodolac, etofenamate, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentiazac, fepradinol, flufenac, flufenamic acid, flunixin, flunoxaprofen, flurbiprofen, glutametacin, glycol salicylate, ibufenac, ibuprofen, ibuproxam, indomethacin, indoprofen, isofezolac, isoxepac, isoxicam, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, metiazinic acid, mofezolac, montelukast, nabumetone, naproxen, niflumic acid, nimesulide, olsalazine, oxaceprol, oxaprozin, oxyphenbutazone,

- a) for a compound of Formula I, where X^2 is $-\text{NHC}(\text{O})-$, by reacting a compound of Formula VI:




VI

wherein L^1 represents a leaving group, and a free amino group of a macrolide represented by Formula VIIa:




VIIa

- b) for a compound of Formula I, where X^2 is $-\text{OC}(\text{O})-$, by reacting a compound of Formula VI and the free hydroxyl group of a macrolide represented by Formula VIIb:






VIIb


- e) for a compound of Formula I, where X^1 is $-\text{CH}_2-$, Q is $-\text{NH}-$ and X^2 is $-\text{NHC(O)}-$, by reacting a macrolide represented by Formula VIIe and a compound of Formula VI:

**VIIe**

- f) for any L compound of Formula I by reacting a macrolide represented by Formula VIIf or by Formula VIIg or by Formula VIIh having a leaving group L^2

**VIIf****VIIg****VIIh**

with a free carboxylic acid of a nonsteroid anti inflammatory subunit represented by the Formula **VIc**:




37. (Original) A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt or solvate of said compound according to claim 1 as well as a pharmaceutically acceptable diluent or carrier.

38. (Currently Amended) A method for the treatment of inflammatory diseases, disorders and conditions characterized by or associated with an undesirable inflammatory immune response, especially of diseases and conditions induced by or associated with an excessive secretion of TNF- α and IL-1 comprising administering to a subject afflicted with one of said disorders or conditions a compound according to claim 1

wherein:


V is chosen from the group consisting of (i) an anti-inflammatory steroid subunit of Formula X:



phenylsalicylate, pyrazolac, piroxicam, pirprofen, pranoprofen, protizinic acid, reserveratol, salacetamide, salicylamide, salicylamide-O-acetyl acid, salicylsulphuric acid, salicin, salicylamide, salsalate, sulindac, suprofen, suxibutazone, tamoxifen, tenoxicam, tiaprofenic acid, tiaramide, ticlopridine, tinoridine, tolfenamic acid, tolmetin, tropesin, xenbucin, ximoprofen, zaltoprofen, zomepirac, tomoxiprol, zafirlukast and cyclosporine.

39. (Currently Amended) A method of treating an inflammatory condition or a an immune or anaphylactic disorder associated with infiltration of leukocytes into inflamed tissue in a subject in need thereof which comprises administering to said subject a therapeutically effective amount of a compound ~~represented by Formula I or a pharmaceutically acceptable salt or solvate thereof~~ according to claim 1 wherein:

V is chosen from the group consisting of (i) an anti-inflammatory steroid subunit of Formula X:



X

wherein

R^a and R^b independently represents, hydrogen or halogen;

R^c is hydroxy, alkoxy, alkyl, thiocarbamoyl, carbamoyl or a valence-bond;

R^d and R^e independently represents: hydrogen, hydroxy, methyl or C₁-C₄-alkoxy or each are a group that forms a 1,3-dioxolane ring with the other or a valence bond;

R^f is hydrogen, hydroxy, chloro, or forming a keto group with the carbon atom it is attached to;

R^j is hydrogen or halogen;

and (ii) a nonsteroidal anti-inflammatory subunit derived from an NSAID selected from the group consisting of: aceclofenac, acemetacin, acetaminophen, acetaminosalol, acetyl-salicylic acid, acetyl-salicylic-2-amino-4-picoline-acid, 5-aminoacetylsalicylic acid, alclofenac, aminoprofen, amfenac, ampyrone, ampiroxicam, anileridine, bendazac, benoxaprofen, bermoprofen, α -bisabolol, bromfenac, 5-bromosalicylic acid acetate, bromosaligenin, bucloxic acid, butibufen, carprofen, celecoxib, chromoglycate, cinmetacin, clindanac, clopirac, sodium diclofenac, diflunisal, ditazol, droxicam, enfenamic acid, etodolac, etofenamate, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentiazac, fepradinol, flufenac, flufenamic acid, flunixin, flunoxaprofen, flurbiprofen, glutametacin, glycol salicylate, ibufenac, ibuprofen, ibuproxam, indomethacin, indoprofen, isofezolac, isoxepac, isoxicam, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, metiazinic acid, mofezolac, montelukast, nabumetone, naproxen, niflumic acid, nimesulide, olsalazine, oxaceprol, oxaprozin, oxyphenbutazone, paracetamol, parsalimide, perisoxal, phenyl-acethyl-salicylate, phenylbutazone, phenylsalicylate, pyrazolac, piroxicam, pirprofen, pranoprofen, protizinic acid, reserveratol, salacetamide, salicylamide, salicylamide-O-acetyl acid, salicylsulphuric acid, salicin, salicylamide, salsalate, sulindac, suprofen, suxibutazone, tamoxifen, tenoxicam, tiaprofenic acid, tiaramide, ticlopridine,

X

wherein

R^a and R^b independently represents, hydrogen or halogen;

R^c is hydroxy, alkoxy, alkyl, thiocarbamoyl, carbamoyl or a valence-bond;

R^d and R^e independently represents: hydrogen, hydroxy, methyl or C₁-C₄-alkoxy or each are a group that forms a 1,3-dioxolane ring with the other or a valence bond;

R^f is hydrogen, hydroxy, chloro, or forming a keto group with the carbon atom it is attached to;

R^j is hydrogen or halogen;

and (ii) a non-steroidal anti-inflammatory subunit derived from the NSAID selected from the group consisting of: aceclofenac, acemetacin, acetaminophen, acetaminosalol, acetyl-salicylic acid, acetyl-salicylic-2-amino-4-picoline-acid, 5-aminoacetylsalicylic acid, alclofenac, aminoprofen, amfenac, ampyrone, ampiroxicam, anileridine, bendazac, benoxaprofen, bermoprofen, α -bisabolol, bromfenac, 5-bromosalicylic acid acetate, bromosaligenin, bucloxic acid, butibufen, carprofen, celecoxib, chromoglycate, cinmetacin, clindanac, clopirac, sodium diclofenac, diflunisal, ditazol, droxicam, enfenamic acid, etodolac, etofenamate, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen, fentiazac, fepradinol, flufenac, flufenamic acid, flunixin, flunoxaprofen, flurbiprofen, glutametacin, glycol salicylate, ibufenac, ibuprofen, ibuproxam, indomethacin, indoprofen, isofezolac, isoxepac, isoxicam, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, metiazinic acid, mofezolac, montelukast, nabumetone, naproxen, niflumic acid, nimesulide, olsalazine, oxaceprol, oxaprozin, oxyphenbutazone,

ifosfamide, hydroxyurea, bleomycin, paclitaxel, lomustine, irinotecan, methotrexate, vinorelbine, anastrozole, floxuridine, melphalan, vincristine, vinblastine, mitomycin, nandrolone, goserelin, leuprolide, triptorelin, aminogluthetamide, mitotane, cisplatin, chlorambucil, pentostatin, cladribine, busulfan, etoposide, mitoxantrone, idarubicin, cyclophosphamide, mercaptopurine, thioguanine, cytarabine, cyclophosphamide, doxorubicin, daunorubicin, teniposide, tamoxifen, taxotere and topotecan.

48. (Original) The method according to claim 47 wherein said symptom or sign is selected from the group consisting of viral load, viral replication, viral activity, viremia, viral-specific antigens, viral RNA, viral DNA, reverse transcriptase activity, antiviral cytotoxic cell activity in the subject, and T-cell or CD4+ cell count of the subject.

49. (Currently Amended) A method of treating a symptom or sign or marker of neoplasia comprising administering to a subject presenting with said symptom or sign a therapeutically effective amount of a compound according to claim 1, wherein V is an antineoplastic subunit derived from the antineoplastic compounds selected from the group consisting of bicalutamide, camptothecin, estramustine phosphate, flutamide, mechlorethamine, thiotepa, ifosfamide, hydroxyurea, bleomycin, paclitaxel, lomustine, irinotecan, methotrexate, vinorelbine, anastrozole, floxuridine, melphalan, vincristine, vinblastine, mitomycin, nandrolone, goserelin, leuprolide, triptorelin, aminogluthetamide, mitotane, cisplatin, chlorambucil, pentostatin, cladribine, busulfan, etoposide, mitoxantrone, idarubicin, cyclophosphamide, mercaptopurine, thioguanine, cytarabine, cyclophosphamide, doxorubicin, daunorubicin, teniposide, tamoxifen, taxotere and topotecan.

50. (Original) The method according to claim 49 wherein said symptom or sign of neoplasia is selected from the group consisting of tumor burden, tumor size, afflicted organ weight, tumor recurrence, survival time, length or extent of subject remission, growth of cancer cells, cancer cell survival, apoptosis index, metastasis extent or metastasis rate, a biological marker associated with a particular type of neoplasia, proliferation markers, activation of relevant oncogenes

